Related references
Note: Only part of the references are listed.Role of the humoral immune response during COVID-19: guilty or not guilty?
Melyssa Yaugel-Novoa et al.
MUCOSAL IMMUNOLOGY (2022)
Use of disease-modifying drugs(tocilizumab, tofacitinib, and baricitinib-a biological or synthetic target specific) in patients hospitalized with COVID-19
Alexandre Naime Barbosa et al.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA (2022)
JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
Lucas Walz et al.
BMC INFECTIOUS DISEASES (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Sairaj Satarker et al.
POSTGRADUATE MEDICINE (2021)
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Patricia O. Guimaraes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
Roman Maslennikov et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2021)
Immunology of COVID-19: Current State of the Science
Nicolas Vabret et al.
IMMUNITY (2020)
COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome
Toshio Hirano et al.
IMMUNITY (2020)
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Yang Cao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19 Definition and Evaluation
Mathias Prokop et al.
RADIOLOGY (2020)
Cytokine release syndrome in severe COVID-19
John B. Moore et al.
SCIENCE (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
Immunomodulatory Drugs in the Management of SARS-CoV-2
Daniel R. Burrage et al.
FRONTIERS IN IMMUNOLOGY (2020)
Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19
De Chang et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)
Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts
Jin Wang et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2020)
Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review
Y. C. Tsai et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)
The regulation of JAKs in cytokine signaling and its breakdown in disease
Henrik M. Hammaren et al.
CYTOKINE (2019)
Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
Massimo Gadina et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa
Patrick P. C. Boor et al.
TRANSLATIONAL RESEARCH (2017)
Tofacitinib: A Review in Rheumatoid Arthritis
Sohita Dhillon
DRUGS (2017)
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Apostolos Kontzias et al.
CURRENT OPINION IN PHARMACOLOGY (2012)